Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9294IDB
  • |
  • Pages: 254
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2017, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Idiopathic Pulmonary Fibrosis-Overview 10

Idiopathic Pulmonary Fibrosis-Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 18

Products under Development by Companies 19

Products under Development by Universities/Institutes 24

Idiopathic Pulmonary Fibrosis-Therapeutics Assessment 25

Assessment by Target 25

Assessment by Mechanism of Action 29

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Idiopathic Pulmonary Fibrosis-Companies Involved in Therapeutics Development 37

AdAlta Ltd 37

Aeolus Pharmaceuticals Inc 37

Allinky Biopharma 38

apceth Biopharma GmbH 38

Apellis Pharmaceuticals Inc 39

Asahi Kasei Pharma Corp 39

aTyr Pharma Inc 40

Biogen Inc 40

Bioneer Corp 41

BLR Bio LLC 41

Bristol-Myers Squibb Company 42

Celgene Corp 42

Celldex Therapeutics Inc 43

Chiesi Farmaceutici SpA 43

Compugen Ltd 44

Cynata Therapeutics Ltd 44

F. Hoffmann-La Roche Ltd 45

FibroGen Inc 45

FibroStatin SL 46

Galapagos NV 46

GenKyoTex SA 47

GlaxoSmithKline Plc 47

Glenmark Pharmaceuticals Ltd 48

Global Blood Therapeutics Inc 48

GNI Group Ltd 49

Histocell SL 49

iBio Inc 50

Inventiva 50

Isarna Therapeutics GmbH 51

Kadmon Corp LLC 51

Kasiak Research Pvt Ltd 52

Kyorin Pharmaceutical Co Ltd 52

Lung Therapeutics Inc 53

Merck & Co Inc 53

miRagen Therapeutics Inc 54

MorphoSys AG 54

Nuevolution AB 55

Pharmaxis Ltd 55

Promedior Inc 56

ProMetic Life Sciences Inc 56

Pulmatrix Inc 57

Re-Pharm Ltd 57

Redx Pharma Plc 58

Respira Therapeutics Inc 58

Ribomic Inc 59

Saje Pharma LLC 59

Samumed LLC 59

Sanofi 60

Sorrento Therapeutics Inc 60

SPR Biosciences LLC 61

Therabron Therapeutics Inc 61

Unity Biotechnology Inc 61

Vicore Pharma AB 62

Yuhan Corp 62

Idiopathic Pulmonary Fibrosis-Drug Profiles 63

AB-22-Drug Profile 63

acALY-18-Drug Profile 64

AD-114-Drug Profile 65

AEOL-10150-Drug Profile 67

AF-102-Drug Profile 77

AIK-3b-Drug Profile 78

Antisense RNAi Oligonucleotide for Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis-Drug Profile 79

Antisense RNAi Oligonucleotide to Inhibit HSP47 for Idiopathic Pulmonary Fibrosis-Drug Profile 80

APL-1-Drug Profile 81

ATYR-1923-Drug Profile 82

BG-00011-Drug Profile 83

BLR-500-Drug Profile 84

BMS-986020-Drug Profile 85

C-21-Drug Profile 86

CC-90001-Drug Profile 89

CDX-0158-Drug Profile 90

CG-1011-Drug Profile 93

CGEN-25009-Drug Profile 94

CM-101-Drug Profile 95

CT-365-Drug Profile 96

CWHM-12-Drug Profile 97

D-9030-Drug Profile 98

FSMAB-26-Drug Profile 99

FST-12-Drug Profile 100

GBT-1118-Drug Profile 101

GBT-440-Drug Profile 102

gefapixant-Drug Profile 108

GKT-831-Drug Profile 112

GLPG-1690-Drug Profile 115

GLPG-2938-Drug Profile 117

GRC-388XX-Drug Profile 118

Grx1-iSPERSE-Drug Profile 119

GSK-3008348-Drug Profile 120

HEC-585-Drug Profile 121

HR-017-Drug Profile 122

IBIOCFB-03-Drug Profile 123

ICG-001-Drug Profile 125

IGP-002-Drug Profile 126

ISTH-0047-Drug Profile 127

IVA-337-Drug Profile 129

KAR-5585-Drug Profile 131

KBP-7018-Drug Profile 132

KD-025-Drug Profile 133

lebrikizumab-Drug Profile 138

LT-1001-Drug Profile 142

LTI-03-Drug Profile 143

MMI-0100-Drug Profile 144

Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis-Drug Profile 146

MOR-107-Drug Profile 147

MRG-201-Drug Profile 148

NAS-911-Drug Profile 150

Neumomir-Drug Profile 152

NUE-7770-Drug Profile 153

OATD-01-Drug Profile 154

OLX-101-Drug Profile 156

OLX-201-Drug Profile 158

omipalisib-Drug Profile 159

P-013-Drug Profile 160

pamrevlumab-Drug Profile 161

PBF-1129-Drug Profile 168

PBI-4050-Drug Profile 169

pirfenidone-Drug Profile 176

pirfenidone-Drug Profile 178

PRI-724-Drug Profile 179

PRM-151-Drug Profile 181

PUR-1500-Drug Profile 186

PXS-4820-Drug Profile 187

RBM-005-Drug Profile 188

RBM-006-Drug Profile 189

Refacell-IPF-Drug Profile 190

RP-0217-Drug Profile 191

RT-1840-Drug Profile 192

RT-234-Drug Profile 193

SAR-156597-Drug Profile 194

SM-04646-Drug Profile 195

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis-Drug Profile 196

Small Molecules for COPD and IPF-Drug Profile 197

Small Molecules for Idiopathic Pulmonary Fibrosis-Drug Profile 198

Small Molecules for Idiopathic Pulmonary Fibrosis-Drug Profile 199

Small Molecules for Idiopathic Pulmonary Fibrosis-Drug Profile 200

Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis-Drug Profile 201

Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis-Drug Profile 202

Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis-Drug Profile 203

Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer-Drug Profile 204

Small Molecules to Inhibit CHIT-1 for IPF and COPD-Drug Profile 205

Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis-Drug Profile 206

Small Molecules to Inhibit MRTF and SRF for Idiopathic Pulmonary Fibrosis-Drug Profile 207

Small Molecules to Inhibit Porcupine for Immunology, Respiratory, Gastrointestinal and Metabolic Disorders-Drug Profile 208

Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis-Drug Profile 209

SPL-334-Drug Profile 210

SPL-334.1-Drug Profile 211

SPL-891.1-Drug Profile 212

Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease-Drug Profile 213

Stem Cell Therapy for Idiopathic Lung Fibrosis and Asthma-Drug Profile 214

Stem Cell Therapy for Idiopathic Pulmonary Fibrosis-Drug Profile 215

Stem Cell Therapy for Idiopathic Pulmonary Fibrosis-Drug Profile 216

Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders-Drug Profile 217

TD-139-Drug Profile 218

thrombomodulin alfa-Drug Profile 219

tipelukast-Drug Profile 221

vismodegib-Drug Profile 226

Wnt-001-Drug Profile 232

YH-siRNA1-Drug Profile 233

ZL-2102-Drug Profile 234

Idiopathic Pulmonary Fibrosis-Dormant Projects 235

Idiopathic Pulmonary Fibrosis-Discontinued Products 238

Idiopathic Pulmonary Fibrosis-Product Development Milestones 239

Featured News & Press Releases 239

Appendix 246

Methodology 246

Coverage 246

Secondary Research 246

Primary Research 246

Expert Panel Validation 246

Contact Us 246

Disclaimer 247

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by AdAlta Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Allinky Biopharma, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by apceth Biopharma GmbH, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Asahi Kasei Pharma Corp, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by aTyr Pharma Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Biogen Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Bioneer Corp, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by BLR Bio LLC, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Celgene Corp, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Celldex Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Chiesi Farmaceutici SpA, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Compugen Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Cynata Therapeutics Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by FibroGen Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by FibroStatin SL, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Galapagos NV, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by GenKyoTex SA, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by GlaxoSmithKline Plc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Global Blood Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by GNI Group Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Histocell SL, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by iBio Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Inventiva, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Isarna Therapeutics GmbH, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Kadmon Corp LLC, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Kasiak Research Pvt Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Lung Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Merck & Co Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by miRagen Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by MorphoSys AG, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Nuevolution AB, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Pharmaxis Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Promedior Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by ProMetic Life Sciences Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Pulmatrix Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Re-Pharm Ltd, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Redx Pharma Plc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Respira Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Ribomic Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Saje Pharma LLC, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Samumed LLC, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Sanofi, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Sorrento Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by SPR Biosciences LLC, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Therabron Therapeutics Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Unity Biotechnology Inc, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Vicore Pharma AB, H1 2017

Idiopathic Pulmonary Fibrosis-Pipeline by Yuhan Corp, H1 2017

Idiopathic Pulmonary Fibrosis-Dormant Projects, H1 2017

Idiopathic Pulmonary Fibrosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Idiopathic Pulmonary Fibrosis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Idiopathic Pulmonary Fibrosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AdAlta Ltd, Aeolus Pharmaceuticals Inc, Allinky Biopharma, apceth Biopharma GmbH, Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp, aTyr Pharma Inc, Biogen Inc, Bioneer Corp, BLR Bio LLC, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Chiesi Farmaceutici SpA, Compugen Ltd, Cynata Therapeutics Ltd, F. Hoffmann-La Roche Ltd, FibroGen Inc, FibroStatin SL, Galapagos NV, GenKyoTex SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Global Blood Therapeutics Inc, GNI Group Ltd, Histocell SL, iBio Inc, Inventiva, Isarna Therapeutics GmbH, Kadmon Corp LLC, Kasiak Research Pvt Ltd, Kyorin Pharmaceutical Co Ltd, Lung Therapeutics Inc, Merck & Co Inc, miRagen Therapeutics Inc, MorphoSys AG, Nuevolution AB, Pharmaxis Ltd, Promedior Inc, ProMetic Life Sciences Inc, Pulmatrix Inc, Re-Pharm Ltd, Redx Pharma Plc, Respira Therapeutics Inc, Ribomic Inc, Saje Pharma LLC, Samumed LLC, Sanofi, Sorrento Therapeutics Inc, SPR Biosciences LLC, Therabron Therapeutics Inc, Unity Biotechnology Inc, Vicore Pharma AB, Yuhan Corp

Idiopathic Pulmonary Fibrosis Therapeutic Products under Development, Key Players in Idiopathic Pulmonary Fibrosis Therapeutics, Idiopathic Pulmonary Fibrosis Pipeline Overview, Idiopathic Pulmonary Fibrosis Pipeline, Idiopathic Pulmonary Fibrosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com